APO RESEARCH · REPORT
Nuclear Medicine & Radiopharmaceuticals
Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.
Product & engineering
Understand the product.
Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.
Selected research
Market Structure
Global Nuclear Medicine & Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.
The major players in Chian Nuclear Medicine & Radiopharmaceuticals market include China Isotope & Radiation, Shanghai Atom Kexing, Advanced Molecular-imaging Solution, etc. Beijing and Chengdu are main markets, they occupy about 65% of the whole market. Diagnostic is the main type, with a share about 80%. Cardiology is the main application, which holds a share about 40%.
This report provides an overview of the global Nuclear Medicine & Radiopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Nuclear Medicine & Radiopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Nuclear Medicine & Radiopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nuclear Medicine & Radiopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.
Nuclear Medicine & Radiopharmaceuticals Segment by Company
China Isotope & Radiation
Dongcheng
Jaco
Ciaeriar
Advanced Molecular-imaging Solution
Shanghai Atom Kexing
Nuclear Medicine & Radiopharmaceuticals Segment by Type
Diagnostic
Therapeutic
Nuclear Medicine & Radiopharmaceuticals Segment by Application
Oncology
Thyroid
Cardiology
Others
Nuclear Medicine & Radiopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine & Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine & Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine & Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nuclear Medicine & Radiopharmaceuticals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nuclear Medicine & Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Diagnostic
- Therapeutic
Applications
- Oncology
- Thyroid
- Cardiology
- Others
Companies covered
- China Isotope & Radiation
- Dongcheng
- Jaco
- Ciaeriar
- Advanced Molecular-imaging Solution
- Shanghai Atom Kexing
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Nuclear Medicine & Radiopharmaceuticals Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Nuclear Medicine & Radiopharmaceuticals Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Nuclear Medicine & Radiopharmaceuticals Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Nuclear Medicine & Radiopharmaceuticals Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Nuclear Medicine & Radiopharmaceuticals Market Dynamics
- 2.1 Nuclear Medicine & Radiopharmaceuticals Industry Trends
- 2.2 Nuclear Medicine & Radiopharmaceuticals Industry Drivers
- 2.3 Nuclear Medicine & Radiopharmaceuticals Industry Opportunities and Challenges
- 2.4 Nuclear Medicine & Radiopharmaceuticals Industry Restraints
3 Nuclear Medicine & Radiopharmaceuticals Market by Manufacturers
- 3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Manufacturers (2021-2026)
- 3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Manufacturers (2021-2026)
- 3.3 Global Nuclear Medicine & Radiopharmaceuticals Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Nuclear Medicine & Radiopharmaceuticals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Nuclear Medicine & Radiopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Nuclear Medicine & Radiopharmaceuticals Manufacturers, Product Type & Application
- 3.7 Global Nuclear Medicine & Radiopharmaceuticals Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Nuclear Medicine & Radiopharmaceuticals Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Nuclear Medicine & Radiopharmaceuticals Players Market Share by Revenue in 2025
- 3.8.3 2025 Nuclear Medicine & Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
4 Nuclear Medicine & Radiopharmaceuticals Market by Type
- 4.1 Nuclear Medicine & Radiopharmaceuticals Type Introduction
- 4.1.1 Diagnostic
- 4.1.2 Therapeutic
- 4.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type
- 4.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Type (2021-2032)
- 4.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Type (2021-2032)
- 4.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type
- 4.3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Type (2021-2032)
- 4.3.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Type (2021-2032)
5 Nuclear Medicine & Radiopharmaceuticals Market by Application
- 5.1 Nuclear Medicine & Radiopharmaceuticals Application Introduction
- 5.1.1 Oncology
- 5.1.2 Thyroid
- 5.1.3 Cardiology
- 5.1.4 Others
- 5.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application
- 5.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Application (2021-2032)
- 5.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Application (2021-2032)
- 5.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application
- 5.3.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Application (2021-2032)
- 5.3.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Application (2021-2032)
6 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region
- 6.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2021-2032)
- 6.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2021-2026)
- 6.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region
- 7.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region
- 7.1.1 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region (2021-2026)
- 7.1.3 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Region (2027-2032)
- 7.1.4 Global Nuclear Medicine & Radiopharmaceuticals Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Nuclear Medicine & Radiopharmaceuticals Revenue (2021-2032)
- 7.2.2 North America Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Nuclear Medicine & Radiopharmaceuticals Revenue (2021-2032)
- 7.3.2 Europe Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Revenue (2021-2032)
- 7.4.2 Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Nuclear Medicine & Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 China Isotope & Radiation
- 8.1.1 China Isotope & Radiation Company Information
- 8.1.2 China Isotope & Radiation Business Overview
- 8.1.3 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.1.5 China Isotope & Radiation Recent Developments
- 8.2 Dongcheng
- 8.2.1 Dongcheng Company Information
- 8.2.2 Dongcheng Business Overview
- 8.2.3 Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Dongcheng Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.2.5 Dongcheng Recent Developments
- 8.3 Jaco
- 8.3.1 Jaco Company Information
- 8.3.2 Jaco Business Overview
- 8.3.3 Jaco Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Jaco Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.3.5 Jaco Recent Developments
- 8.4 Ciaeriar
- 8.4.1 Ciaeriar Company Information
- 8.4.2 Ciaeriar Business Overview
- 8.4.3 Ciaeriar Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Ciaeriar Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.4.5 Ciaeriar Recent Developments
- 8.5 Advanced Molecular-imaging Solution
- 8.5.1 Advanced Molecular-imaging Solution Company Information
- 8.5.2 Advanced Molecular-imaging Solution Business Overview
- 8.5.3 Advanced Molecular-imaging Solution Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Advanced Molecular-imaging Solution Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.5.5 Advanced Molecular-imaging Solution Recent Developments
- 8.6 Shanghai Atom Kexing
- 8.6.1 Shanghai Atom Kexing Company Information
- 8.6.2 Shanghai Atom Kexing Business Overview
- 8.6.3 Shanghai Atom Kexing Nuclear Medicine & Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Shanghai Atom Kexing Nuclear Medicine & Radiopharmaceuticals Product Portfolio
- 8.6.5 Shanghai Atom Kexing Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Nuclear Medicine & Radiopharmaceuticals Value Chain Analysis
- 9.1.1 Nuclear Medicine & Radiopharmaceuticals Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Nuclear Medicine & Radiopharmaceuticals Production Mode & Process
- 9.2 Nuclear Medicine & Radiopharmaceuticals Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Nuclear Medicine & Radiopharmaceuticals Distributors
- 9.2.3 Nuclear Medicine & Radiopharmaceuticals Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst